UChicago Medicine patient first in the world to receive ulcerative colitis drug since FDA approval (The University of Chicago Medicine)

A 35-year-old patient at the University of Chicago Medicine became the first person globally to receive Tremfya (guselkumab) after its FDA approval for treating moderate to severe ulcerative colitis. The drug, previously used for psoriasis and psoriatic arthritis, was shown to be effective for ulcerative colitis in a study led by Dr. David T. Rubin at UChicago Medicine.